Kyverna Therapeutics, Inc. Common Stock (KYTX)vsRoyalty Pharma Plc (RPRX)
KYTX
Kyverna Therapeutics, Inc. Common Stock
$7.47
-6.04%
HEALTHCARE · Cap: $490.62M
RPRX
Royalty Pharma Plc
$55.02
-1.38%
HEALTHCARE · Cap: $31.60B
Smart Verdict
WallStSmart Research — data-driven comparison
RPRX leads profitability with a 33.9% profit margin vs 0.0%. RPRX earns a higher WallStSmart Score of 65/100 (C+).
KYTX
Avoid28
out of 100
Grade: F
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for KYTX.
Margin of Safety
-53.4%
Fair Value
$34.53
Current Price
$55.02
$20.49 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : KYTX
The strongest argument for KYTX centers on Debt/Equity, Price/Book.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : KYTX
The primary concerns for KYTX are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
KYTX profiles as a value stock while RPRX is a mature play — different risk/reward profiles.
KYTX carries more volatility with a beta of 1.96 — expect wider price swings.
RPRX is growing revenue faster at 11.0% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 28/100), backed by strong 33.9% margins and 11.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kyverna Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Kyverna Therapeutics, Inc. is a pioneering biotechnology firm dedicated to the development of advanced immunotherapies targeting autoimmune diseases and other critical health conditions. Leveraging its proprietary genetically engineered T-cell technology, the company strives to enhance immune system functionality, delivering specialized therapeutic solutions that aim to significantly improve patient outcomes. With a strong focus on cellular therapies, Kyverna is strategically positioned to take advantage of the burgeoning biopharmaceutical market, making it an attractive opportunity for institutional investors seeking to invest in innovative treatments within the rapidly evolving immunotherapy space.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?